First Selective Covalent FGFR3 Inhibitors: Conquering Toxicity and Resistance

Pan-FGFR inhibitors face toxicity and acquired resistance in FGFR3-altered cancers. This Viewpoint highlights the first covalent FGFR3-selective inhibitor, a promising agent addressing isoform selectivity and clinically acquired resistance in targeted therapy.

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-02-27
DOI
https://doi.org/10.1021/acs.jmedchem.6c00492
Primary Topic
Fibroblast Growth Factor Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

First Selective Covalent FGFR3 Inhibitors: Conquering Toxicity and Resistance

Journal of Medicinal Chemistry
Fibroblast Growth Factor Research
article

First Selective Covalent FGFR3 Inhibitors: Conquering Toxicity and Resistance

article en

Abstract

Pan-FGFR inhibitors face toxicity and acquired resistance in FGFR3-altered cancers. This Viewpoint highlights the first covalent FGFR3-selective inhibitor, a promising agent addressing isoform selectivity and clinically acquired resistance in targeted therapy.

Journal of Medicinal ChemistryVol. 69(5)
Sichuan University (CN)
Good health and well-being
Openalex Percentile: Top 40%
Fibroblast Growth Factor Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.